Yun Choi1, Catherine S Diefenbach2. 1. NYU Langone Hematology & Medical Oncology Fellowship Program, 550 First Avenue, New York, NY, 10016, USA. 2. Division of Hematology and Medical Oncology, Perlmutter Cancer Center at NYU Langone Health, New York University School of Medicine, Langone Medical Center, 240 East 38th Street, 19th Floor, New York, NY, 10016, USA. catherine.diefenbach@nyulangone.org.
Abstract
PURPOSE OF REVIEW: The landscape of relapsed or refractory (R/R) Hodgkin lymphoma (HL) treatment has changed significantly since the FDA approval of brentuximab vedotin in 2011. In this review, we summarize the recent advances in the therapy for R/R classical Hodgkin lymphoma (cHL). RECENT FINDINGS: Immunotherapies with pembrolizumab, nivolumab, and ipilimumab, and chimeric antigen receptor (CAR) T cell therapies have shown promising results in early phase trials. Other novel agents under investigation include targeted therapies with histone deacetylase inhibitors, Janus kinase 2 inhibitors, and immunomodulators. While further studies with larger populations and longer follow-up times are needed to determine the safe and effective combinations, these novel approaches represent a growing list of treatment options that are on the horizon to improve the cure rate and increase duration of remission for R/R HL patients.
PURPOSE OF REVIEW: The landscape of relapsed or refractory (R/R) Hodgkin lymphoma (HL) treatment has changed significantly since the FDA approval of brentuximab vedotin in 2011. In this review, we summarize the recent advances in the therapy for R/R classical Hodgkin lymphoma (cHL). RECENT FINDINGS: Immunotherapies with pembrolizumab, nivolumab, and ipilimumab, and chimeric antigen receptor (CAR) T cell therapies have shown promising results in early phase trials. Other novel agents under investigation include targeted therapies with histone deacetylase inhibitors, Janus kinase 2 inhibitors, and immunomodulators. While further studies with larger populations and longer follow-up times are needed to determine the safe and effective combinations, these novel approaches represent a growing list of treatment options that are on the horizon to improve the cure rate and increase duration of remission for R/R HLpatients.
Authors: T Baetz; A Belch; S Couban; K Imrie; J Yau; R Myers; K Ding; N Paul; L Shepherd; J Iglesias; R Meyer; M Crump Journal: Ann Oncol Date: 2003-12 Impact factor: 32.976
Authors: A F Herrera; J Palmer; P Martin; S Armenian; N-C Tsai; N Kennedy; F Sahebi; T Cao; L E Budde; M Mei; T Siddiqi; L Popplewell; S T Rosen; L W Kwak; A Nademanee; S J Forman; R Chen Journal: Ann Oncol Date: 2018-03-01 Impact factor: 32.976
Authors: Joseph M Connors; Wojciech Jurczak; David J Straus; Stephen M Ansell; Won S Kim; Andrea Gallamini; Anas Younes; Sergey Alekseev; Árpád Illés; Marco Picardi; Ewa Lech-Maranda; Yasuhiro Oki; Tatyana Feldman; Piotr Smolewski; Kerry J Savage; Nancy L Bartlett; Jan Walewski; Robert Chen; Radhakrishnan Ramchandren; Pier L Zinzani; David Cunningham; Andras Rosta; Neil C Josephson; Eric Song; Jessica Sachs; Rachael Liu; Hina A Jolin; Dirk Huebner; John Radford Journal: N Engl J Med Date: 2017-12-10 Impact factor: 91.245
Authors: Craig H Moskowitz; Matt J Matasar; Andrew D Zelenetz; Stephen D Nimer; John Gerecitano; Paul Hamlin; Steven Horwitz; Alison J Moskowitz; Ariela Noy; Lia Palomba; Miguel-Angel Perales; Carol Portlock; David Straus; Jocelyn C Maragulia; Heiko Schoder; Joachim Yahalom Journal: Blood Date: 2011-12-19 Impact factor: 22.113
Authors: M Picardi; R Della Pepa; C Giordano; N Pugliese; C Mortaruolo; F Trastulli; M G Rascato; I Cappuccio; M Raimondo; M Memoli; M Monteverde; M Mascolo; F Pane Journal: Blood Adv Date: 2019-05-14
Authors: Margaretha G M Roemer; Ranjana H Advani; Azra H Ligon; Yasodha Natkunam; Robert A Redd; Heather Homer; Courtney F Connelly; Heather H Sun; Sarah E Daadi; Gordon J Freeman; Philippe Armand; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Scott J Rodig; Margaret A Shipp Journal: J Clin Oncol Date: 2016-04-11 Impact factor: 44.544
Authors: Philippe Armand; Yi-Bin Chen; Robert A Redd; Robin M Joyce; Jad Bsat; Erin Jeter; Reid W Merryman; Kimberly C Coleman; Parastoo B Dahi; Yago Nieto; Ann S LaCasce; David C Fisher; Samuel Y Ng; Oreofe O Odejide; Arnold S Freedman; Austin I Kim; Jennifer L Crombie; Caron A Jacobson; Eric D Jacobsen; Jeffrey L Wong; Sanjay S Patel; Jerome Ritz; Scott J Rodig; Margaret A Shipp; Alex F Herrera Journal: Blood Date: 2019-04-05 Impact factor: 25.476
Authors: Daniel Fowler; Callum Nattress; Alba Southern Navarrete; Marta Barisa; Jonathan Fisher Journal: Cancers (Basel) Date: 2021-11-29 Impact factor: 6.639
Authors: Jana Mihályová; Katarína Hradská; Tomáš Jelínek; Benjamin Motais; Piotr Celichowski; Roman Hájek Journal: Int J Mol Sci Date: 2021-10-25 Impact factor: 5.923